Develops drugs for rare kidney and neurodegenerative diseases.
Dec 2025Revenue $0.00/yrExpenses $153M/yr
No trendCash runway ≈ 2.0 years from Jun 2026
Figures by year
When will Amylyx Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $153M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $153M | −$153M |
| Dec 2024 | $87.4M | $402M | −$315M |
| Dec 2023 | $381M | $342M | $38.8M |
| Dec 2022 | $22.2M | $224M | −$201M |
| Dec 2021 | $285K | $83.0M | −$82.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.